Sun Outstrips Viatris’ Pentasa Action Date With First ANDA Approval
Analyst Forecasts Launch Could Add Up To $70m In Revenues
Sun Pharma has scooped a first ANDA approval for a rival to Takeda’s mesalamine-containing brand Pentasa, with Viatris making clear recently that it was eyeing a first-time generic launch for the gastrointestinal drug.
